top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Mark Velleca Biography and Net Worth

Director of G1 Therapeutics

Dr. Mark Velleca was the Chief Executive Officer of G1 from 2014 to 2020 and remains a board member and Senior Advisor to the company. Previously, he served as Executive Vice President at the Leukemia & Lymphoma Society (LLS). Prior to LLS, Mark was a co-founder and Senior Vice President of CGI Pharmaceuticals, where he managed the company from its inception through clinical trials of multiple drug candidates. After Gilead Sciences acquired CGI, he served as a Senior Advisor to Gilead in R&D Strategy and Corporate Development.

Earlier in his career, Mark was an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine.

Mark is currently a Venture Partner at Hatteras Venture Partners, board chair at Turbine AI, and a board member at IMMvention Therapeutix.

Mark earned an M.D. and Ph.D. from Washington University in St. Louis, and a B.S. from Yale University.

What is Mark A. Velleca's net worth?: The estimated net worth of Mark A. Velleca is at least $462,840.00 as of October 18th, 2022. Dr. Velleca owns 116,000 shares of G1 Therapeutics stock worth more than $462,840 as of April 25th. This net worth estimate does not reflect any other assets that Dr. Velleca may own. Learn More about Mark A. Velleca's net worth.
How do I contact Mark A. Velleca?: The corporate mailing address for Dr. Velleca and other G1 Therapeutics executives is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. G1 Therapeutics can also be reached via phone at (919) 213-9835 and via email at [email protected]. Learn More on Mark A. Velleca's contact information.
Has Mark A. Velleca been buying or selling shares of G1 Therapeutics?: Mark A. Velleca has not been actively trading shares of G1 Therapeutics over the course of the past ninety days. Most recently, Mark A. Velleca sold 15,000 shares of the business's stock in a transaction on Tuesday, October 18th. The shares were sold at an average price of $11.70, for a transaction totalling $175,500.00. Following the completion of the sale, the director now directly owns 116,000 shares of the company's stock, valued at $1,357,200. Learn More on Mark A. Velleca's trading history.
Who are G1 Therapeutics' active insiders?: G1 Therapeutics' insider roster includes John Bailey, Jr. (CEO), James Hanson (General Counsel), Rajesh Malik (Insider), and Mark Velleca (Director). Learn More on G1 Therapeutics' active insiders.
Are insiders buying or selling shares of G1 Therapeutics?: In the last year, insiders at the sold shares 10 times. They sold a total of 110,255 shares worth more than $397,880.45. The most recent insider tranaction occured on March, 18th when CFO John W V Umstead sold 6,547 shares worth more than $19,771.94. Insiders at G1 Therapeutics own 8.2% of the company. Learn More about insider trades at G1 Therapeutics.
Information on this page was last updated on 3/18/2024.

Mark A. Velleca Insider Trading History at G1 Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/18/2022	Sell	15,000	$11.70	$175,500.00	116,000
9/20/2022	Sell	20,000	$13.50	$270,000.00	116,000
8/16/2022	Sell	80,000	$12.64	$1,011,200.00	116,000
7/15/2021	Sell	10,000	$18.49	$184,900.00	71,000
7/13/2021	Sell	10,000	$19.45	$194,500.00	71,000
6/17/2021	Sell	10,000	$21.77	$217,700.00	71,000
6/15/2021	Sell	10,000	$22.39	$223,900.00	71,000
5/13/2021	Sell	30,000	$19.90	$597,000.00
5/11/2021	Sell	10,000	$19.10	$191,000.00	51,000
4/14/2021	Sell	10,000	$24.53	$245,300.00	51,000
2/18/2021	Sell	10,000	$26.02	$260,200.00	52,040
2/16/2021	Sell	11,040	$35.20	$388,608.00	52,040
1/20/2021	Sell	10,000	$21.51	$215,100.00	47,000
12/17/2020	Sell	30,000	$19.53	$585,900.00	47,000
12/15/2020	Sell	10,000	$19.43	$194,300.00	47,000
10/15/2018	Sell	5,000	$41.53	$207,650.00
8/15/2018	Sell	5,000	$55.88	$279,400.00
7/16/2018	Sell	5,000	$42.06	$210,300.00
5/15/2018	Sell	7,500	$46.28	$347,100.00
4/16/2018	Sell	7,500	$36.00	$270,000.00
12/18/2017	Sell	7,500	$20.01	$150,075.00

Mark A. Velleca Buying and Selling Activity at G1 Therapeutics

G1 Therapeutics Company Overview

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Today's Range

Now: $3.99

$3.94

$4.24

50 Day Range

MA: $3.69

$2.15

$4.88

2 Week Range

Now: $3.99

$1.08

$5.00

Volume

343,795 shs

Average Volume

1,300,499 shs

Market Capitalization

$208.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.73